Researchers have utilized fluoxetine [19] and artemisinin [20] to mitigate cognitive dysfunction in AD and T2DM mice by reducing Aβ1-40 and Aβ1-42 levels in the hippocampus and activating the hippocampal PI3K/Akt pathway, respectively, thereby enhancing hippocampal neuronal synaptic plasticity. This evidence concerns the gene AKT1 and type 2 diabetes mellitus.